02/07/2012 09:59 .
Having detected therapeutic activity in preclinical and clinical trials with PM01183 in breast cancer, PharmaMar is commencing a Phase II trial with the drug.
The endpoint is to confirm PM01183's activity in patients with breast cancer.
Hospitals in Spain and the US are participating in this trial.
Madrid, 2 July 2012: After launching Phase II trials in pancreatic and platinum- resistant ovarian cancer, PharmaMar is commencing a Phase II trial with its PM01183 compound in breast cancer. The endpoint is to evaluate the compound's antitumour activity as second- to fourth-line treatment in patients with this illness.
At least 50 (first phase) and at most 117 evaluable patients will be treated in the hospitals participating in this important trial.
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.